<DOC>
	<DOCNO>NCT00035152</DOCNO>
	<brief_summary>Taxol carboplatin commonly use drug treatment stage IIIB IV non small cell lung carcinoma . This study compare treatment Taxol/carboplatin give every 3 week schedule give weekly . The purpose study determine effective safe schedule give drug non small cell lung carcinoma .</brief_summary>
	<brief_title>Study Comparing Weekly Taxol Carboplatin v Standard Taxol Carboplatin Regimen Stage IIIB IV Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Confirmation nonsmall cell bronchogenic carcinoma ( epidermoid , squamous , adeno , large cell anaplastic carcinoma , small cell carcinoid ) must histologically cytologically confirm . No prior antineoplastic chemotherapy , hormonal therapy therapy biological response modifier No previous irradiation area measurable disease . Past current history neoplasm entry diagnosis . Exceptions curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix cancer treat surgery radiation disease free survival longer 5 year . Patients undergone surgery le 3 week prior enrollment . History serious cardiac disease adequately control . Patients serious active infection serious underlie medical condition . Uncontrolled diabetes mellitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>